Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations

Leukemia. 2007 Mar;21(3):383-6. doi: 10.1038/sj.leu.2404509.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Developed Countries / classification
  • Developed Countries / economics
  • Drug Costs
  • Europe / epidemiology
  • Health Care Costs
  • Hematopoietic Stem Cell Transplantation / economics*
  • Hematopoietic Stem Cell Transplantation / statistics & numerical data
  • Humans
  • Imatinib Mesylate
  • Income
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / economics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / epidemiology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery*
  • Piperazines / economics
  • Piperazines / therapeutic use
  • Pyrimidines / economics
  • Pyrimidines / therapeutic use
  • Societies, Medical / statistics & numerical data
  • Transplantation, Homologous / economics
  • Transplantation, Homologous / statistics & numerical data

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate